Journal of Clinical Endocrinology & Metabolism, Vol 49, 757-764, Copyright © 1979 by Endocrine Society

ARTICLES

A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol

S Ulick, LS Levine, P Gunczler, G Zanconato, LC Ramirez, W Rauh, A Rosler, HL Bradlow and MI New

A syndrome is described whose features, suggestive of primary mineralcorticoid excess, included hypertension, hypokalemia, low PRA, and responsiveness to spironolactone. Aldosterone levels were subnormal but as yet there has been no evidence of overproduction of other mineralocorticoids by chemical analysis or by bioassay of plasma and urinary extracts. The steroidal abnormalities that were observed involved peripheral matabolism rather than secretion. One patient exhibited a transient delay in reduction of the 3-keto group in the A ring, and both patients exhibited a decrease in the metabolism of cortisol to biologically inactive cortisone. This was shown by the marked decrease in the excretion of urinary metabolites bearing an 11- keto group and a decrease in the oxidation of 11 alpha-[3H]cortisol to tritiated water. The defect appeared not to be a deficiency of the 11 beta-oxidoreductase system itself, since the reverse reaction of conversion of cortisone to cortisol proceeded normally, but, rater, an alteration in the equilibrium position of 11 beta-oxidoreduction in favor of the reduced form. This was also expressed by a prolongation of the half-time of disappearance of cortisol. The decrease in the MCR permitted the maintenance of normal cortisol plasma levels and normal glucocorticoid function at a diminished rate of secretion. The decreased rate of conversion of cortisol to cortisone serves as a biochemical marker of this hypertensive syndrome.

This article has been cited by other articles:

				A. E. Michael and A. T. Papageorghiou Potential significance of physiological and pharmacological glucocorticoids in early pregnancy Hum. Reprod. Update, September 1, 2008; 14(5): 497 - 517. [Abstract] [Full Text] [PDF]

				B. Chamarthi, N. S. Kolatkar, S. C. Hunt, J. S. Williams, E. W. Seely, N. J. Brown, L. J. Murphey, X. Jeunemaitre, and G. H. Williams Urinary Free Cortisol: An Intermediate Phenotype and a Potential Genetic Marker for a Salt-Resistant Subset of Essential Hypertension J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1340 - 1346. [Abstract] [Full Text] [PDF]

				H. C. Thiesson, B. L. Jensen, C. Bistrup, P. D. Ottosen, A. D. McNeilly, R. Andrew, J. Seckl, and O. Skott Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R625 - R636. [Abstract] [Full Text] [PDF]

				G. Morineau, V. Sulmont, R. Salomon, B. Fiquet-Kempf, X. Jeunemaitre, J. Nicod, and P. Ferrari Apparent Mineralocorticoid Excess: Report of Six New Cases and Extensive Personal Experience J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3176 - 3184. [Abstract] [Full Text] [PDF]

				V. E. Murphy, R. Smith, W. B. Giles, and V. L. Clifton Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus Endocr. Rev., April 1, 2006; 27(2): 141 - 169. [Abstract] [Full Text] [PDF]

				M. Quinkler, D. Zehnder, J. Lepenies, M. D Petrelli, J. S Moore, S. V Hughes, P. Cockwell, M. Hewison, and P. M Stewart Expression of renal 11{beta}-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function Eur. J. Endocrinol., August 1, 2005; 153(2): 291 - 299. [Abstract] [Full Text] [PDF]

				N. Draper and P. M Stewart 11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action J. Endocrinol., August 1, 2005; 186(2): 251 - 271. [Abstract] [Full Text] [PDF]

				N. Glorioso, F. Filigheddu, P. P. Parpaglia, A. Soro, C. Troffa, G. Argiolas, and P. Mulatero 11{beta}-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension Eur. Heart J., March 1, 2005; 26(5): 498 - 504. [Abstract] [Full Text] [PDF]

				M. Quinkler and P. M. Stewart Hypertension and the Cortisol-Cortisone Shuttle J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2384 - 2392. [Abstract] [Full Text] [PDF]

				C. A. Carvajal, A. A. Gonzalez, D. G. Romero, A. Gonzalez, L. M. Mosso, E. T. Lagos, M. d. P. Hevia, M. P. Rosati, T. O. Perez-Acle, C. E. Gomez-Sanchez, et al. Two Homozygous Mutations in the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene in a Case of Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2501 - 2507. [Abstract] [Full Text] [PDF]

				P. Ferrari, M. G. Bianchetti, A. Sansonnens, and F. J. Frey Modulation of Renal Calcium Handling by 11{beta}-Hydroxysteroid Dehydrogenase Type 2 J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2540 - 2546. [Abstract] [Full Text] [PDF]

				P. Ferrari, A. Sansonnens, B. Dick, and F. J. Frey In Vivo 11{beta}-HSD-2 Activity: Variability, Salt-Sensitivity, and Effect of Licorice Hypertension, December 1, 2001; 38(6): 1330 - 1336. [Abstract] [Full Text] [PDF]

				P. Heilmann, E. Buchheim, J. Wacker, and R. Ziegler Alteration of the Activity of the 11{beta}-Hydroxysteroid Dehydrogenase in Pregnancy: Relevance for the Development of Pregnancy-Induced Hypertension? J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5222 - 5226. [Abstract] [Full Text] [PDF]

				W Shamim, M Yousufuddin, D P Francis, P Gualdiero, J W Honour, S D Anker, and A J S Coats Raised urinary glucocorticoid and adrenal androgen precursors in the urine of young hypertensive patients: possible evidence for partial glucocorticoid resistance Heart, August 1, 2001; 86(2): 139 - 144. [Abstract] [Full Text] [PDF]

				J. R. Seckl and B. R. Walker Minireview: 11{beta}-Hydroxysteroid Dehydrogenase Type 1-- A Tissue-Specific Amplifier of Glucocorticoid Action Endocrinology, April 1, 2001; 142(4): 1371 - 1376. [Abstract] [Full Text]

				A. Odermatt, B. Dick, P. Arnold, T. Zaehner, V. Plueschke, M. N. Deregibus, H. Repetto, B. M. Frey, F. J. Frey, and P. Ferrari A Mutation in the Cofactor-Binding Domain of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1247 - 1252. [Abstract] [Full Text]

				K. E. Sheppard, S. Hourigan, K. X. Z. Li, and Z. S. Krozowski Novel nuclear corticosteroid binding in rat small intestinal epithelia Am J Physiol Gastrointest Liver Physiol, September 1, 2000; 279(3): G536 - G542. [Abstract] [Full Text] [PDF]

				M. I. New and R. C. Wilson Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess PNAS, October 26, 1999; 96(22): 12790 - 12797. [Abstract] [Full Text] [PDF]

				E. Lovati, P. Ferrari, B. Dick, K. Jostarndt, B. M. Frey, F. J. Frey, U. Schorr, and A. M. Sharma Molecular Basis of Human Salt Sensitivity: The Role of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3745 - 3749. [Abstract] [Full Text] [PDF]

				K. E. Sheppard, K. X. Z. Li, and D. J. Autelitano Corticosteroid receptors and 11beta -hydroxysteroid dehydrogenase isoforms in rat intestinal epithelia Am J Physiol Gastrointest Liver Physiol, September 1, 1999; 277(3): G541 - G547. [Abstract] [Full Text] [PDF]

				G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess Hypertension, September 1, 1999; 34(3): 435 - 441. [Abstract] [Full Text] [PDF]

				D. Rogoff, Z. Smolenicka, I. Bergadá, G. Vallejo, M. Barontini, J. J. Heinrich, and P. Ferrari The Codon 213 of the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene Is a Hot Spot for Mutations in Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4391 - 4393. [Abstract] [Full Text]

				D. Fuster, G. Escher, B. Vogt, D. Ackermann, B. Dick, B. M. Frey, and F. J. Frey Furosemide Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Endocrinology, September 1, 1998; 139(9): 3849 - 3854. [Abstract] [Full Text] [PDF]

				R. C. Wilson, S. Dave-Sharma, J.-Q. Wei, V. R. Obeyesekere, K. Li, P. Ferrari, Z. S. Krozowski, C. H. L. Shackleton, L. Bradlow, T. Wiens, et al. A genetic defect resulting in mild low-renin hypertension PNAS, August 18, 1998; 95(17): 10200 - 10205. [Abstract] [Full Text] [PDF]

				S. Dave-Sharma, R. C. Wilson, M. D. Harbison, R. Newfield, M. R. Azar, Z. S. Krozowski, J. W. Funder, C. H. L. Shackleton, H. L. Bradlow, J.-Q. Wei, et al. Examination of Genotype and Phenotype Relationships in 14 Patients with Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2244 - 2254. [Abstract] [Full Text]

				K. E. Sheppard, K. Khoo, Z. S. Krozowski, and K. X. Z. Li Steroid specificity of the putative DHB receptor: evidence that the receptor is not 11beta HSD Am J Physiol Endocrinol Metab, July 1, 1998; 275(1): E124 - E131. [Abstract] [Full Text] [PDF]

				D. J. Morris, S. A. Latif, M. D. Rokaw, C. O. Watlington, and J. P. Johnson A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy Am J Physiol Cell Physiol, May 1, 1998; 274(5): C1245 - C1252. [Abstract] [Full Text] [PDF]

				S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension Cardiovasc Res, April 1, 1998; 38(1): 16 - 24. [Abstract] [Full Text] [PDF]

				D. J. Morris, Y. H. Lo, W. R. Lichtfield, and G. H. Williams Impact of Dietary Na+ on Glycyrrhetinic Acid-Like Factors (Kidney 11{beta}-(HSD2)-GALFs) in Human Essential Hypertension Hypertension, January 1, 1998; 31(1): 469 - 472. [Abstract] [Full Text] [PDF]

				S. Kitanaka, N. Katsumata, A. Tanae, I. Hibi, K.-I. Takeyama, H. Fuse, S. Kato, and T. Tanaka A New Compound Heterozygous Mutation in the 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene in a Case of Apparent Mineralocorticoid Excess J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4054 - 4058. [Abstract] [Full Text] [PDF]

				G. Morineau, A. Boudi, A. Barka, M. Gourmelen, F. Degeilh, N. Hardy, A. Al-Halnak, H. Soliman, J. P. Gosling, R. Julien, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol–cortisone shuttle Clin. Chem., August 1, 1997; 43(8): 1397 - 1407. [Abstract] [Full Text] [PDF]

				K. X. Z. Li, V. R. Obeyesekere, Z. S. Krozowski, and P. Ferrari Oxoreductase and Dehydrogenase Activities of the Human and Rat 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Enzyme Endocrinology, July 1, 1997; 138(7): 2948 - 2952. [Abstract] [Full Text] [PDF]

				G. Morineau, J. Gosling, M.-C. Patricot, H. Soliman, P. Boudou, A. A. Halnak, G. Le Brun, J.-L. Brerault, R. Julien, J.-M. Villette, et al. Convenient chromatographic prepurification step before measurement of urinary cortisol by radioimmunoassay Clin. Chem., May 1, 1997; 43(5): 786 - 793. [Abstract] [Full Text] [PDF]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]

				Y. H. Lo, M. F. Sheff, S. A. Latif, C. Ribeiro, H. Silver, A. S. Brem, and D. J. Morris Kidney 11{beta}-HSD2 Is Inhibited by Glycyrrhetinic Acid-Like Factors in Human Urine Hypertension, January 1, 1997; 29(1): 500 - 505. [Abstract] [Full Text] [PDF]

				P. C. White Inherited Forms of Mineralocorticoid Hypertension Hypertension, December 1, 1996; 28(6): 927 - 936. [Abstract] [Full Text]

				B. Watson, S. M. Bergman, A. Myracle, D. F. Callen, R. T. Acton, and D. G. Warnock Genetic Association of 11ß-Hydroxysteroid Dehydrogenase Type 2 (HSD11B2) Flanking Microsatellites With Essential Hypertension in Blacks Hypertension, September 1, 1996; 28(3): 478 - 482. [Abstract] [Full Text]

				T. Mune and P. C. White Apparent Mineralocorticoid Excess : Genotype Is Correlated With Biochemical Phenotype Hypertension, June 1, 1996; 27(6): 1193 - 1199. [Abstract] [Full Text]

				G. W. Souness and D. J. Morris 11{alpha}- and 11ß-Hydroxyprogesterone, Potent Inhibitors of 11ß-Hydroxysteroid Dehydrogenase, Possess Hypertensinogenic Activity in the Rat Hypertension, March 1, 1996; 27(3): 421 - 425. [Abstract] [Full Text]

				B. R. Walker, R. Best, C. H.L. Shackleton, P. L. Padfield, and C. R.W. Edwards Increased Vasoconstrictor Sensitivity to Glucocorticoids in Essential Hypertension Hypertension, February 1, 1996; 27(2): 190 - 196. [Abstract] [Full Text]

				Y. Takeda, I. Miyamori, K. Iki, S. Inaba, K. Furukawa, H. Hatakeyama, T. Yoneda, and R. Takeda Endogenous Renal 11ß-Hydroxysteroid Dehydrogenase Inhibitory Factors in Patients With Low-Renin Essential Hypertension Hypertension, February 1, 1996; 27(2): 197 - 201. [Abstract] [Full Text]

				P. C. White Disorders of Aldosterone Biosynthesis and Action N. Engl. J. Med., July 28, 1994; 331(4): 250 - 258. [Full Text]

				K. E. Sheppard Nuclear Receptors: II. Intestinal corticosteroid receptors Am J Physiol Gastrointest Liver Physiol, May 1, 2002; 282(5): G742 - G746. [Abstract] [Full Text] [PDF]